A Study to Evaluate the Incidence and Clinical Characteristics of Interstitial Lung Disease (ILD) Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKIs) Gefitinib or Erlotinib in Taiwanese Patients with Adavanced Non Small Cell Lung Cancer (NSCLC)

Trial Profile

A Study to Evaluate the Incidence and Clinical Characteristics of Interstitial Lung Disease (ILD) Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKIs) Gefitinib or Erlotinib in Taiwanese Patients with Adavanced Non Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top